Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JACOB: SGT-53, Nivolumab, and Radiation in Pediatric Recurrent CNS Malignancies
NCT07017816Phase 1Recruiting
- Sponsor
- Children's National Research Institute
- Start
- Dec 2025
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGT-53 in central nervous system malignancy, sponsored by Children's National Research Institute. Primary endpoint: Frequency and type of toxicity deemed at least probably related to SGT-53. Started Dec 2025; status: recruiting.
02
Drugs
SGT-53
03
Conditions
central nervous system malignancy
Beyond the preview
Go deeper on NCT07017816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017816.